Profile picture

Doctor Efthymios Ziogos

The Johns Hopkins University School of Medicine, Baltimore (United States of America)
Membership: ESC Professional Member
Follow
Logo ESC

Contributor content

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab decreases myocardial inflammation in individuals with acute coronary syndrome (ACS)
Presentation
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab decreases myocardial inflammation in individuals with acute coronary syndrome (ACS)
Read more
Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and interaction with the vascular endothelium: the impact of PCSK9 inhibition with evolocumab in acute coronary syndrome
Presentation
Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and interaction with the vascular endothelium: the impact of PCSK9 inhibition with evolocumab in acute coronary syndrome
Read more

ESC 365 is supported by

novartis Explore sponsored resources